Surgical Science Sweden Ab · OMXSTO:SUS

Surgical Science Sweden Ab — Q3 2024 Earnings Presentation

10 slides from Surgical Science Sweden Ab's earnings presentation, Nov 14, 2024

  1. Slide 1: Presentation of Interim Report Q3

    Surgical Science Presentation of Interim Report Q3 November 14, 2024 ©2024 Surgical Science. | All Rights Reserved.

  2. Slide 2: CEO comments – Q3

    CEO comments – Q3  Continued increased momentum in Edu Products, +2% revenue Surgical Science’s new - +17% growth vs Q2 Pediatric Advanced Echo - Big tenders materialize in sales module was launched in - Stronger customer activity in all markets, but Edu Products will not show FY growth Q3, and off

  3. Slide 3: Q3: Sales growth for both business areas

    Q3: Sales growth for both business areas SEKm Q3: 250  Net sales was up 10% to SEKm 231.8 (210.2). In local currencies up 12%. 200 38% 38% 46% 45% 33% 41% 40% 150 48%  Educational Products’ sales was up 2%. India 58% strong dev, China on par. Europe: Poland and Bulgaria strong. US on par, larger o

  4. Slide 4: Revenue streams – strong simulator sales

    REVENUE STREAMS – strong simulator sales SEKm 250 3%  License rev’s: 28 (26) percent of total 2% 2% 3% 4% revenues. Lumpy for new entrants, 200 5% 25% 6% 4% revenues from several customers. 5% 31% 28% 33% 20% 35% 26% 32% 8% 150 8% 8% 34% 10%  Simulator sales strongest since Q4 9% 9% 10% 10% 2022.

  5. Slide 5: Costs and EBIT margin Q3 2024

    COSTS AND EBIT MARGIN Q3 2024  Gross margin 69% (69). Increased share of license revenues (28 vs 26%) had a positive effect. Product mix favorable, ASP slightly lower.  Sales: Lower activity re. congresses than Q1 and Costs of goods sold 31% (31) Q2. Offset by higher agent fees. 18% (18) of Sales

  6. Slide 6: Organization – 60+ markets covered

    ORGANIZATION No of employees at end of period: 270 (260) Men 196 (186) Women 74 (74) Israel 139 (134) Sweden 61 (57) 60+ markets covered USA 54 (54) Other 16 (15) * Offices / Development sites * Other: Primarily Germany and China. ©2024 Surgical Science. | All Rights Reserved.

  7. Slide 7: Adjusted EBIT

    ADJUSTED EBIT SEKm Q3: 250 50% 45%  Adjusted EBIT SEKm 51.8 (56.9), margin 22% (27). 200 40% 35% 150 30% 25% YTD: 100 20% 15%  Adjusted EBIT SEKm 50 10% 123.4 (169.8), margin 20% (26). 5% 0 0% Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2022 2023 2024 Net sales Adjusted EBIT Adjusted EBIT % ©2024 Surgical Science.

  8. Slide 8: Finance net and taxes

    FINANCE NET AND TAXES  Finance net for the quarter SEKm 7.2 (1.7). Interest on bank balances, revaluation of internal loans towards subsidiaries and IFRS 16 effect.  Net result for the quarter SEKm 43.0 (47.4). ©2024 Surgical Science. | All Rights Reserved.

  9. Slide 9: Cash flow

    CASH FLOW SEKm  Cash flow from operating activities SEKm 700 25% 22.1 (53.1). Change in working capital 600 SEKm -32.5 (-15.0). Inventory changed 20% marginally, A/R increased significantly. 500 400 15%  Cash flow from investing activities mainly investments in development costs. 300 10% 200  Exc

  10. Slide 10: Thank you

    Thank you Find out more at: www.surgicalscience.com Tom Englund, CEO tom.englund@surgicalscience.com Anna Ahlberg, CFO anna.ahlberg@surgicalscience.com

Surgical Science Sweden — Q3 2024 Earnings Presentation on 6ix